There was also no significant association between ORAI1 variants and COVID-19 fatality (Fig 3, Table 3), despite its role in immune cell function and the promising outcome of ORAI1 inhibition in the randomized, controlled, open-label study conducted in patients with severe or critical COVID-19 pneumonia [20]. Here, ORAI1 is linked to COVID-19.